Log inSign up
OncoAlert
122.9K posts
user avatar
OncoAlert
@OncoAlert
🌐 Worldwide oncology professionals network | Run by oncologists, for colleagues | All tumor types | Non-profit 🚨 We are #OncoAlert | Oncology360°
Worldwide
OncoAlert360.com
Joined March 2019
137
Following
42K
Followers

New to X?

Sign up now to get your own personalized timeline!

Create account

By signing up, you agree to the Terms of Service and Privacy Policy, including Cookie Use.

Terms·Privacy·Cookies·Accessibility·Ads Info·© 2026 X Corp.
Don't miss what's happening
People on X are the first to know.
Log inSign up
  • Pinned
    user avatar
    OncoAlert
    @OncoAlert
    4h
    The OncoAlert Newsletter June 25- July 1, ,2026 REGISTER TO GET IT👉 buff.ly/X6N7qLU or buff.ly/4xd4naf 🔥 Highlights include: 🔹 Industry Update: 🇪🇺 EU approval of trastuzumab deruxtecan as the first tumour-agnostic HER2-directed ADC for previously treated
    00:00
    893
  • OncoAlert reposted
    user avatar
    ASCO
    @ASCO
    3h
    ASCO Special Awards have two NEW honors this year! 🌟 💠 Community Legacy Award (for community oncologists expanding local care) 💠Cancer Care Impact Award (for members directly expanding cancer care delivery) Nominate by July 15: bit.ly/4eWonKv
    1.2K
  • OncoAlert reposted
    user avatar
    ACS Journal Cancer
    @JournalCancer
    2h
    New editorial by Erin Van Blarigan ScD (@UCSF_Epibiostat) & Justin Brown PhD (@AdventHealth) discusses how the ACES expert panel consensus statement helps fill a critical gap in exercise recommendations for older cancer survivors. acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… @OncoAlert #GeriOnc
    229
  • OncoAlert reposted
    user avatar
    OncoAlert
    @OncoAlert
    Jul 6
    Dear Colleagues 🌐 We ARE ALL OncoAlert 🚨 @weoncologists @DrChoueiri @CharlesSwanton @FAndreMD @tompowles1 @peters_solange @jrgralow @hoperugo @montypal @apolo_andrea @neerajaiims @christine_lovly @Silke_Gillessen @AOmlin @brian_rini @JavierCortesMD @CathyEngMD @matteolambe
    2K
  • user avatar
    OncoAlert
    @OncoAlert
    6h
    Antibody–drug conjugates beyond HER2: Translating evidence into practice for HR+ HER2-negative and triple-negative metastatic breast cancer buff.ly/8L9mYsi Antibody–drug conjugates (ADCs) have transformed treatment for HER2-negative metastatic #BreastCancer ,
    798
  • user avatar
    OncoAlert
    @OncoAlert
    7h
    The #WeekInOncology by @OncoAlert 🚨 Dr. Uğur Özkerim 🇹🇷 breaks down his top #LungCancer 🫁 picks: 📊 PACIFIC trial post hoc analysis (Lancet Oncology) 📰 KRAScendo-1 industry update Top trials. Top faculty. Every week. Only on OncoAlert 👇 PACIFIC Link
    00:00
    3K
  • OncoAlert reposted
    user avatar
    Jame Abraham, MD, FACP
    @jamecancerdoc
    8h
    Excellent opportunity for Leadership Development through @ASCO !
    user avatar
    ASCO
    @ASCO
    21h
    Ready to guide the future of oncology? Applications are open for our 2027-28 ASCO Leadership Development Program (LDP)! Transform into a next-gen leader through a 1-year immersive curriculum w/ mentorship, expert training, & a great group of peers: bit.ly/44KGTAL
    1.2K
  • user avatar
    OncoAlert
    @OncoAlert
    7h
    Circulating Tumor DNA in Early Breast Cancer (Review) buff.ly/zKVN1V9 Circulating tumor DNA (ctDNA) is a promising noninvasive biomarker for detecting minimal residual disease, monitoring treatment response, and identifying recurrence in early #BreastCancer . While
    853
  • OncoAlert reposted
    user avatar
    Elvina Almuradova
    @Dr_ElvinaA
    12h
    Proud to be a co-author of this multicentre Turkish Oncology Group study evaluating the 10-year risk of second primary malignancies among chemotherapy-treated early-stage breast cancer survivors. In a cohort of 6,552 women, breast cancer survivors had a significantly increased
    690
  • OncoAlert reposted
    user avatar
    IJGC
    @IJGConline
    18h
    New #IJGCconversations episode 🚨 Sarah Andres and Mario M. Leitao Jr. @leitaomd discuss about the empty lymph node packet in SLN mapping for #endometrialcancer 🎧 Tune in now! bit.ly/4vWreKU @pedroramirezMD @RParejaGineOnco @HsuMd @JayrajAarthi @AndreFernandes2
    00:00
    721
  • OncoAlert reposted
    user avatar
    Dra. María Natalia Gandur Quiroga
    @nataliagandur
    20h
    🚨 Can we improve on the current adjuvant standard in high-risk ccRCC? @OncoAlert @NEJM @DrChoueiri @OpenMedicineHQ @OpenMedInsights The phase 3 LITESPARK-022 trial suggests the answer may be yes. Adding belzutifan to pembrolizumab after surgery improved disease-free survival
    user avatar
    NEJM
    @NEJM
    Jul 4
    In patients with resected clear-cell renal-cell carcinoma, pembrolizumab plus belzutifan led to higher disease-free survival than pembrolizumab alone but with an increased risk of grade 3 or higher adverse events. Watch a new Quick Take video on the phase 3 LITESPARK-022 trial:
    This image contains illustrations from the Quick Take "Pembrolizumab plus Belzutifan in Renal-Cell Carcinoma." On the left, there's an IV bag labeled "Pembrolizumab." Next to it is a container labeled "Belzutifan" with tablets. In the center, a silhouette of a patient shows highlighted kidneys. On the right, a close-up of the left kidney with resected clear-cell renal-cell carcinoma.
    1.5K
  • OncoAlert reposted
    user avatar
    Paolo Ciracì
    @p_ciracimd
    10h
    Replying to @p_ciracimd
    Full paper (@OncoAlert)
    Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases
    From jamanetwork.com
    427
  • OncoAlert reposted
    user avatar
    OncoAlert
    @OncoAlert
    Jul 6
    [177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial buff.ly/XK5LsTc The COMPETE phase 3 trial compared [177Lu]Lu-edotreotide with everolimus in patients
    1.7K